Ultomiris
Showing 1 - 23 of 23
Healthy Trial in London (ALXN1210 SC, ALXN1210 IV, Placebo)
Completed
- Healthy
- ALXN1210 SC
- +2 more
-
London, United KingdomClinical Trial Site
Mar 11, 2022
Neuromyelitis Optica Spectrum Disorder Trial in Barcelona (Ravulizumab)
Recruiting
- Neuromyelitis Optica Spectrum Disorder
-
Barcelona, SpainClinical Trial Site
Jul 6, 2022
Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial in Worldwide (BCX9930, Eculizumab, Ravulizumab)
Active, not recruiting
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- BCX9930
- +2 more
-
Paris, France
- +6 more
Dec 15, 2022
Paroxysmal Nocturnal Hemoglobinuria Trial in Worldwide (Ravulizumab)
Active, not recruiting
- Paroxysmal Nocturnal Hemoglobinuria
- Ravulizumab
-
Atlanta, Georgia
- +8 more
Aug 15, 2022
Paroxysmal Nocturnal Hemoglobinuria Trial in Whittier (Cemdisiran, Eculizumab, Pozelimab)
Recruiting
- Paroxysmal Nocturnal Hemoglobinuria
- Cemdisiran
- +3 more
-
Whittier, CaliforniaRegeneron Research Facility
Jan 28, 2022
Paroxysmal Nocturnal Hemoglobinuria Trial in Leeds, London (Eculizumab, Ravulizumab)
Active, not recruiting
- Paroxysmal Nocturnal Hemoglobinuria
- Eculizumab
- Ravulizumab
-
Leeds, United Kingdom
- +1 more
Sep 21, 2021
Paroxysmal Nocturnal Hemoglobinuria Trial in Whittier (Ravulizumab, Pozelimab, Cemdisiran)
Recruiting
- Paroxysmal Nocturnal Hemoglobinuria
- Ravulizumab
- +2 more
-
Whittier, California
- +8 more
Nov 29, 2022
Paroxysmal Nocturnal Hemoglobinuria, PNH Trial in Worldwide (Ravulizumab)
Completed
- Paroxysmal Nocturnal Hemoglobinuria
- PNH
- Ravulizumab
-
Toronto, Ontario, Canada
- +15 more
Dec 7, 2022
Atypical Hemolytic Uremic Syndrome (aHUS) Trial in Worldwide (Ravulizumab)
Active, not recruiting
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Ravulizumab
-
Aurora, Colorado
- +19 more
Nov 16, 2022
Covid19, Thrombotic Microangiopathies, Acute Kidney Injury Trial in Boston (Ravulizumab)
Active, not recruiting
- Covid19
- +2 more
-
Boston, MassachusettsBrigham and Women's Hospital
Dec 31, 2022
Thrombotic Microangiopathy Trial in Worldwide (Ravulizumab, Best Supportive Care)
Active, not recruiting
- Thrombotic Microangiopathy
- Ravulizumab
- Best Supportive Care
-
Birmingham, Alabama
- +57 more
Jan 31, 2023
Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial in Worldwide (Ravulizumab, Eculizumab)
Completed
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Ravulizumab
- Eculizumab
-
Duarte, California
- +48 more
Jul 14, 2022
Thrombotic Microangiopathy Trial in Worldwide (Ravulizumab, Placebo, Best supportive care)
Recruiting
- Thrombotic Microangiopathy
- Ravulizumab
- +2 more
-
Tampa, Florida
- +90 more
Jan 26, 2023
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Recruiting
- Paroxysmal Nocturnal Hemoglobinuria
-
Boston, MassachusettsContact the PNH Registry at Alexion Pharmaceuticals, Inc. for wo
Dec 7, 2021
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder Trial in Worldwide (Ravulizumab)
Active, not recruiting
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder
- Ravulizumab
-
Birmingham, Alabama
- +67 more
Feb 3, 2022
Amyotrophic Lateral Sclerosis, ALS Trial in Worldwide (Placebo, Ravulizumab)
Terminated
- Amyotrophic Lateral Sclerosis
- ALS
- Placebo
- Ravulizumab
-
Phoenix, Arizona
- +94 more
Dec 15, 2022